[Acute coronary syndromes in patients treated with HIV protease inhibitors].
BACKGROUND
Cardiovascular complications occurring in patients infected by the human immunodeficient virus (HIV) have considerably changed since the appearance, in April 1996, of highly active antiretroviral tri-therapy (HAART), associating reverse transcriptase and protease HIV-1 inhibitors. The spectacular efficacy of anti-proteases has led to the almost complete disappearance of these opportunistic complications. However, in May 1998, acute coronary accidents were reported in the literature, thus questioning the possible responsibility of antiprotease treatment in the occurrence of accelerated atheroma.


METHODS
We report a series of 8 seropositive patients in whom an acute coronary event had occurred between February 1997 and February 1999.


RESULTS
The patients were young and all exhibited cardiovascular risk factors (smoking, dyslipidemia) and were treated with HIV-1 protease inhibitors. Six patients presented myocardial infarction, one patient unstable angina and one patient effort angina.


CONCLUSIONS
A rise in triglycerides was observed principally on ingestion of ritonavir and a rise in cholesterol and LDL-cholesterol with all the antiprotease agents. Glucose intolerance was observed with indinavir. The occurrence of acute coronary events appeared to be related to antiprotease treatment (at the origin of metabolic disorders, endothelial dysfunction...), although it was impossible to say whether the antiprotease agents were responsible for the early atheroma or whether they simply contributed to the event. The coronary lesions were characterized by their number (single artery) and their topography (proximal or median). Nelfinavir may carry less cardiovascular risks than the other antiproteases. Mean term prognosis was relatively good, after therapeutic adjustment (change in antiprotease, strategic measures against cardiovascular risk factors, introduction of anti-anginal treatment...).


CONCLUSIONS
Larger and longer studies would help to specify the role of antiproteases in the occurrence of early coronary events. Rigorous monitoring (lipid and glucose measurements, tests to search for myocardial infarction,..) together with the development of new antiretroviral molecules would reduce the number of coronary events in this type of patient.
Barthélémy
O
O
Service de Cardiologie, Hôpital Cochin, 27 rue du Fg Saint-Jacques, F75679 Paris. olivier.barthelemy@nck.ap-hop-paris.fr
Escaut
L
L
Vayre
F
F
Gallet
B
B
Pulik
M
M
Heloire
F
F
Vittecoq
D
D
D000328:Adult; D000787:Angina Pectoris / Q000209:etiology*; D000789:Angina, Unstable / Q000209:etiology; D002784:Cholesterol / Q000097:blood; D015658:HIV Infections / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology*; D012307:Risk Factors; D019438:Ritonavir / Q000008:administration & dosage / Q000627:therapeutic use; D019258:Saquinavir / Q000008:administration & dosage / Q000627:therapeutic use; D012907:Smoking / Q000009:adverse effects; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D017320:HIV Protease Inhibitors; D014280:Triglycerides; D019469:Indinavir; D002784:Cholesterol; D019258:Saquinavir; D019438:Ritonavir